Search Results

Affluent Medical Names Dr. Howard C. Herrmann as Chief Medical Officer

March 14, 2025—Affluent Medical recently announced the appointment of Howard C. Herrmann, MD, as Strategic Chief Medical Officer (CMO) for its structural heart platform.

Outcomes From Prosthesis–Patient Mismatch in TAVR Evaluated in TVT Registry

September 24, 2018—Findings on prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) were presented at TCT 2018, the 30th annual Transcatheter Cardiovascular Therapeutics scientific symposium held September 21–25 in San Diego, California, and simultaneously published online by Howard C. Herrmann, MD, et al in Journal of the American College of Cardiology (JACC).

SMART Evaluates Medtronic’s Evolut TAVR to Treat Symptomatic Aortic Stenosis and Small Aortic Annulus

May 26, 2026—Medtronic announced 3-year results of the SMART international head-to-head comparative trial of transcatheter aortic valve replacement (TAVR) with the company’s Evolut self-expanding system versus the Sapien balloon-expandable system (Edwards) to treat patients with symptomatic aortic stenosis and a small aortic annulus.

Medtronic CoreValve/Evolut TAVR Systems’ Performance Evaluated in Updated Analyses

June 7, 2024—Medtronic announced new data from the CoreValve Evolut clinical program, evaluating the performance of the company’s Evolut transcatheter aortic valve replacement (TAVR) system compared to surgical aortic valve replacement (SAVR) and other TAVR devices.

SMART Compares Evolut and Sapien TAVR Devices in Patients With Small Valve Annuli

April 7, 2024—The American College of Cardiology (ACC) announced that findings from the SMART trial demonstrated that patients with a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR) with a supra-annular self-expanding valve had similar clinical outcomes and superior valve performance at 1 year compared with patients who underwent TAVR with a balloon-expandable valve.

Randomized SMART Trial Will Evaluate Medtronic’s Evolut Pro and Pro+ TAVR Systems in Small Annulus Patients

October 14, 2020—Medtronic announced it will begin two studies, the SMART postmarket trial and EXPAND TAVR I feasibility study, of its Evolut transcatheter aortic valve replacement (TAVR) technology.

Medtronic’s Evolut TAVR Studied for Patients with Small Annuli in SMART

March 12, 2025—Medtronic recently announced 2-year results from the SMART trial of transfemoral transcatheter aortic valve replacement (TAVR) in patients with symptomatic severe aortic stenosis and a small aortic annulus.

FINESSE Studies Facilitated Reperfusion PCI

October 19, 2009—In the Journal of American College of Cardiology: Cardiovascular Interventions, Stephen G. Ellis, MD, et al published an evaluation of 12-month outcomes of facilitated percutaneous coronary intervention (PCI) in the FINESSE (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events) trial (2009;2:909-916).

One-Year PARTNER II Data Presented for Edwards' Sapien 3 TAVR System in High-Risk and Inoperable Patients

October 15, 2015—One-year patient outcomes from the PARTNER II trial showed that the low rate of 30-day complications with Edwards Lifesciences’ Sapien 3 balloon-expandable transcatheter aortic valve replacement (TAVR) system in high-risk and inoperable patients with aortic stenosis persisted with follow up to 1 year.

SMART Analysis Compares Hemodynamic Performance of Self-Expanding and Balloon-Expandable TAVR Devices

May 3, 2024—An analysis from the SMART trial demonstrated clinical noninferiority of self-expanding versus balloon-expandable valves in patients with aortic stenosis (AS) and small aortic annuli (SAA) undergoing transcatheter aortic valve replacement (TAVR).

Effect of Prosthesis-Patient Mismatch in TAVR Studied for Women Versus Men

May 1, 2025—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the presentation of data demonstrating that women are 8% more likely than men to experience major complications after transcatheter aortic valve replacement (TAVR).

Medtronic ALERT Study Seeks to Address Disparities in Structural Heart Disease Treatment

November 20, 2024—Medtronic announced the beginning of the randomized study ALERT study, which will use an integrated electronic health record (EHR) platform to address the undertreatment of severe aortic stenosis (AS) or moderate-to-severe or severe mitral regurgitation (MR) and evaluate the racial, ethnic, gender, and geographic disparities associated with guideline-recommended treatments such as transcatheter aortic valve replacement (TAVR).

Medtronic Survey Highlights Need for Increased Awareness Among Women of Heart Valve Disease

April 11, 2024—Medtronic recently announced findings of its comprehensive survey on women’s perceptions and knowledge of risk factors, treatment patterns, and preventive care practices related to heart valve disease.